Played a leading role in global botulinum toxin companies like Allergan and Merz. Set to take lead in Hugel’s successful expansion into the US, Canada and Australia.
[Infostock Daily= Reporter Song Jeong-hoon] Hugel, a global total medical aesthetic company, named James P. Hartman as President of Hugel America, its North American subsidiary.
Mr. Hartman has extensive experience and knowledge in the medical aesthetics space. He joins Hugel from Alastin Skincare, a derma cosmetics company where he served as Chief Commercial Officer. While at Alastin, he was integral in leading the team to market leading growth, increasing revenues by more than 250% while developing strategies and building out a commercial team to drive this achievement. Prior to joining Alastin Skincare, he was at Merz Aesthetics, a division of Merz North America where he was Vice President & U.S. Head of Aesthetics & OTC. He has significant experience in the Aesthetics / Dermatology segment which includes senior leadership roles at Obagi, Stiefel and Allergan.
In particular, Mr. Hartman participated in the launch of the world's first botulinum toxin product ‘Botox’ and successfully launched the product, opening the doors of the global botulinum toxin market. Also, as Vice President of Merz North America, he developed a portfolio strategy that combines botulinum toxin, medical devices and skin care products. He has earned reputation as a sales/marketing expert in the medical aesthetics field, achieving 40+% annual revenue growth in the fourth year of launch of the botulinum toxin product 'Xeomin' through strategic marketing practices.
According to Jihoon Sohn, CEO of Hugel, “James Hartman is a seasoned expert in the medical aesthetic field with abundant commercial experiences and proven track record of building differentiated brands. We are excited to work with him to successfully launch Hugel’s products in the US, Canada and Australia through innovative and strategic approaches. As we near the final steps in preparing for the US expansion, we will make every effort to successfully enter and win in the US market with Mr. Hartman in the lead."
Hugel established its North America, Australia and New Zealand subsidiary ‘Hugel America’ in October 2018 with an Austrian-based pharmaceutical company ‘Croma Pharma’. Through the subsidiary, which is 70% owned by Hugel, it directly operates distribution and marketing of its products in the U.S., Canada, Australia and New Zealand. Hugel plans to submit the BLA to FDA around the end of this year to enter the U.S. market and expects to obtain a final approval by the end of next year.
Reorter Song Jeong-hoon boxr@infostock.co.kr
